SUMMARY
Methicillin-resistant Staphylococcus aureus (MRSA) is a major problem in patients requiring intensive care including mechanical ventilation 1 . Bloodstream and lower airway infections due to MRSA are associated with substantial morbidity and mortality 2, 3 . Detection and control of imported and acquired methicillin-resistant S. aureus (MRSA) has been recognised to contribute to prevention of transmission and subsequent nosocomial infection. The patients are considered as an animate source of MRSA contributing to transmission.
The only evidence-based method for the prevention of pneumonia and mortality in mechanically ventilated patients is selective decontamination of the digestive tract (SDD) 4, 5 . The meta-analysis of randomized controlled trials (RCTs) in medical/surgical patients has shown that SDD reduces the odds ratio for pneumonia to 0.35 (95% confidence interval: 0.29-0.41) and mortality to 0.78 (95% confidence interval: 0.68-0.89) with an overall mortality reduction from 29% to 24% 4 . The most recent RCT in about 1000 patients demonstrated even a greater treatment effect of 8% absolute mortality reduction 5 . The target microorganisms of SDD are the "community" pathogens including Streptococcus pneumoniae and methicillin-sensitive S. aureus (MSSA) and the "opportunistic" aerobic Gram-negative (AGNB) including Klebsiella, Enterobacter, Acinetobacter and Pseudomonas species 6 . MRSA, by design, is not covered by SDD and hence, six RCTs conducted in intensive care units (ICUs) where MRSA was endemic at the time of the study, showed a trend towards higher MRSA infection rates in patients receiving SDD [7] [8] [9] [10] [11] [12] . These observations suggest that the antimicrobials of the SDD protocol, i.e., parenteral cefotaxime and enteral polymyxin, tobramycin and amphotericin B, select and promote MRSA. Under these circumstances SDD requires the addition of oropharyngeal and intestinal vancomycin. Six of the 53 RCTs on SDD evaluated the efficacy of vancomycin applied topically in the oropharynx using a solution 13, 14 or a paste 15, 16 and a solution in stomach and gut 14, 17, 18 . Although these six RCTs evaluated topical vancomycin in throat and/or gut in different concentrations, the addition of oropharyngeal and enteral vancomycin to the classical SDD, was reported to be effective in the prevention of MRSA, without any harmful side-effects.
Surveillance samples of throat and gut are an integral part of the prophylactic protocol of SDD in order to monitor its efficacy 6 . These samples processed in a semi-quantitative way allow the estimation of the absolute carriage by multiplying the proportion of long stay patients who are carriers of MRSA by the level of carriage. For example, the absolute carriage is significantly higher when 50% of the long stay patients carry MRSA in overgrowth concentrations of 3, i.e., the absolute carriage is 1.5, than when only 50% carry MRSA in low concentrations of 1, i.e. an absolute carriage of 0.5. The absolute carriage reflects the long-term ventilated patients as the animate source of the ICU strain(s). The higher the absolute carriage of the particular strain on the ICU, the higher the risk of patients for acquiring the existing strain(s). In other words, the exposure to which a newly admitted patient is subjected to for acquiring MRSA directly relates to the absolute carriage of MRSA.
More than one decade ago, infection prophylaxis using SDD was implemented in the intensive care unit at the University Hospital of Trieste, Italy, in all patients requiring prolonged mechanical ventilation of three days or more. When MRSA became endemic in the unit at the end of the nineties 19 , there was the opportunity to undertake a prospective study to compare the impact of a 2% vancomycin oral gel versus a 4% vancomycin gel on the absolute carriage and subsequent infection due to MRSA. The safety of the enteral vancomycin policy in terms of the emergence of S. aureus with intermediate sensitivity to vancomycin (VISA) and of vancomycin-resistant enterococci (VRE) was assessed over the two year study.
PATIENTS AND METHODS

Setting
The University Hospital of Trieste is a multidisciplinary, regional referral centre. The intensive care unit is an eleven bed facility with an annual admission rate of approximately 700 patients, medical and surgical patients each accounting for 45% of the population, the remaining 10% are trauma. The overall mortality rate is 15% for all admissions.
Patients
All adult patients (aged 18 years) likely to require mechanical ventilation for a minimum of three days, as judged by the responsible intensivist based on the patient's clinical condition and underlying disease, were considered eligible and then were consecutively included in this prospective, observational, two-year cohort study, conducted between March 1, 1998 and February 29, 2000. Patients were excluded if aged <18 years, not requiring prolonged mechanical ventilation and having a fatal coexisting disease 20 . The illness severity was estimated on admission using the Simplified Acute Physiology Score (SAPS II). Surveillance samples from throat and rectum of eligible patients were obtained on admission and twice weekly afterwards (Monday and Thursday). Diagnostic samples were taken on clinical indications only. Data collection stopped when the patient was extubated, died or discharged from the ICU. The Hospital Institutional Review Board waived the need for informed consent, because of the epidemiological nature of the study and absence of invasive procedures.
Intervention
Immediately the surveillance cultures yielded MRSA, either from the oropharynx or the rectum in any concentration, the vancomycin protocol was commenced (Table 1) . One millilitre of gel was applied four times daily in the lower cheeks to eradicate oropharyngeal MRSA carriage. The first year, between March 1, 1998 and February 28, 1999 , a 2% concentration equivalent to a total daily dose of 80 mg was evaluated (Group A), whilst the vancomycin concentration was increased to 4% (a total daily dose of 160 mg) during the second year (group B) from 1st March 1999 to 29th February 2000. Throughout the two year study, all eligible patients with surveillance samples positive for MRSA received a total daily dose of 1.0 gram of vancomycin in four doses through the nasogastric tube. The vancomycin protocol was discontinued once two consecutive sets of throat and rectum samples were MRSA negative. Both gel and solution were prepared by the hospital pharmacy.
Design
A sequential rather than a randomized design was chosen in order to avoid "contamination bias" 21 . Contamination bias may occur when the likelihood that both patient populations-albeit receiving different vancomycin doses-benefit from the intervention evaluated, is high, as concurrent patients in a randomized design are subjected to a lower risk of acquisition, carriage and infection. This dilution due to the subset of patients receiving the lower doses being present with the patients receiving the higher doses, at the same time in the same unit, may erode the distinctiveness of the two groups.
Endpoints
This sequential two year study was undertaken to evaluate three microbiological and clinical endpoints:
i. The impact of a 2% vancomycin gel on the absolute carriage compared with a 4% vancomycin gel; ii. The impact of the 2% vancomycin gel versus 4% vancomycin gel on the secondary endogenous infections due to MRSA; iii. The emergence of VISA and of VRE, in both surveillance and diagnostic samples, as a possible side effect of enteral vancomycin.
Antibiotic policy
• Prophylaxis All patients received infection prevention using SDD immediately on admission to the ICU until extubation or discharge [4] [5] [6] . Half a gram of an oral paste containing tobramycin 2%, polymyxin E 2% and amphotericin B 2% was applied in the lower cheeks and 9 ml of a suspension containing 80 mg of tobramycin, 100 mg of polymyxin E and 500 mg of amphotericin B was administered through the nasogastric tube four times daily. Cefotaxime 100 mg/ kg/day in patients admitted from the community or ceftazidime 100 mg/kg/day in subjects referred from the hospital was given IV immediately on admission to the ICU for four days.
• Treatment Parenteral antimicrobials, including vancomycin, were administered when clinical, laboratory and microbiological criteria of infection were established and guided by the results of the microbiology laboratory. Antibiotic courses were always seven days followed by re-evaluation of the patient.
Tracheostomy policy
A surgical tracheostomy was placed as a primary procedure in patients with trauma to assist in the management of brain, face and jaw (burn) injuries, or of crushing chest trauma with cervical spinal injury. Patients anticipated to require intubation for a few extra weeks after an initial period of ten days, received a tracheostomy as a secondary procedure late in the clinical course.
Microbiology
Surveillance Samples
Surveillance samples of throat and rectal swabs were processed qualitatively and semi-quantitatively, to detect the level of carriage. Three solid mediaMacConkey (Biolife, Milan, Italy), staphylococcal without mannitol (Biomerieux, Marcy L'Etoile, France), and yeast agar (Biokar Diagnostics, Milan, Italy) -were inoculated using the four-quadrant method combined with brain-heart infusion broth. Each swab was streaked onto the three solid media, then the tip was broken off into 5 ml of enrichment broth. The MacConkey plate was examined after one night and the staphylococcal and yeast plates, after two nights. Additionally, if the enrichment broth was turbid after one night's incubation it was then inoculated onto the three media. Semi-quantitative estimation was made by grading growth density on a scale of 1+ to 5+ (Table 2) 22 . Standard methods for identification, typing, and sensitivity patterns were used for all microorganisms. Differentiation of S. aureus from other species of staphylococci was ascertained by production of DNAse (by a DNA agar-plate method) and a slideagglutination test to detect clumping factor and protein A (Pastorex Staph Plus, Sanofi Diagnostics, Marnes, France). When results were inconclusive, a tube-coagulase test with the NCTC 6571 strain as a positive control was undertaken and interpreted at 4 and 24 hours. Coagulase-negative staphylococcus was identified by a negative tube-coagulation test.
S. aureus isolates were tested for methicillin susceptibility by subculturing the isolates onto nutrient agar plus 5% salt (Oxoid, Basingstoke, U.K.) with a strip containing 25 µg of oxacillin. S. aureus isolates growing up to the strip and subsequently shown to have an MIC >256 µg/ml in the exponential antibiotic gradient (E)-test, were confirmed to be MRSA.
Diagnostic Samples
Blood, lower airway secretions, urine and other secretions were processed in a qualitative and semiquantitative way using standard microbiological methods.
Macroscopically distinct colonies were isolated in pure culture for all types of samples. Standard methods for identification, typing, and sensitivity patterns were used for all microorganisms.
Definitions
Absolute carriage of a particular (resistant) potential pathogen was defined as the product of the percentage of the patients who carry the particular strain (carrier rate) times the mean of the semi-quantitative estimates of the concentrations of the strain in a set of surveillance samples (average level of carriage) obtained from the carriers at a particular time on the ICU. Absolute carriage estimates the magnitude of the animate source represented by the patients who are carriers of that strain.
Overgrowth was defined as the presence of high concentrations of MRSA, 3+ or 10 5 colony forming units (CFU)/ml, in the digestive tract (Table 2) 23 . Colonization was defined as the presence of microorganisms in a body site which is normally sterile, e.g. lower airways, bladder. Diagnostic samples from lower airway secretions, wound fluid and urine yield <3+ or <10
5 CFU/ml of diagnostic sample. Generally, only a few (+) leucocytes are present in colonized internal organs, on a semi-quantitative scale of + = few, ++ = moderate and +++ = many leucocytes 24 . Infection is a microbiologically proven, clinical diagnosis of inflammation, local and/or generalized.
This includes not only clinical signs but also the presence of minimally a moderate (++) number of leucocytes, and of 3+ or 10 5 CFU/ml of diagnostic samples obtained from an internal organ, or the isolation of a microorganism from a blood culture.
According to the carrier state classification 6, 25 , the infectious episodes can be defined as: -Primary endogenous caused by both "community"
and "hospital" microorganisms that are already carried on admission to the ICU. -Secondary endogenous caused by microorganisms acquired in the digestive tract after admission to the ICU. These organisms usually belong to the "hospital" group. Potentially pathogenic microorganisms (PPM) including MRSA are usually transmitted via the hands of healthy staff and are first acquired in the oropharynx, followed by carriage and overgrowth in the digestive tract. Clinical diagnosis only: Criteria 1-4 above and sterile BAL or tracheal aspirate.
Tracheitis/bronchitis 1. Purulent tracheal aspirate and 2. Fever ≥ 38.5°C and 3. Leucocytosis (WBC >12000/ml) or leucopaenia (WBC <4000/ml) and 4. Tracheal aspirate yielding ≥ 10 5 CFU/ml 5. Most importantly, the chest X-ray is negative.
Sepsis
Clinical signs of generalized inflammation caused by microorganisms and/or their products.
Bloodstream infection
Sepsis in combination with positive blood cultures.
Central venous catheter related infection Clinical picture of bloodstream infection in which the central venous line was considered the only obvious source of infection (exclusion criterion).
Septic shock
Sepsis in combination with clinical signs of inadequate perfusion of tissue beds.
Intra-abdominal infection
Infection of an abdominal organ and of the peritoneal cavity (peritonitis) with local signs such as abdominal tenderness and generalized symptoms including fever and leucocytosis. Peritonitis can be a localized or general infection of the peritoneal cavity. Following ultrasound and computed tomography scan the diagnosis is confirmed by the isolation of microorganisms of ≥ 3+ or ≥ 10 5 CFU/ml and ≥ ++ leucocytes in the diagnostic sample.
Urinary tract infection
Infection of the urinary tract, most commonly the bladder. The common features of dysuria, suprapubic pain, frequency and urgency are not present in the ICU patients, therefore the diagnosis of cystitis is based on fresh voided catheter urine containing ≥ 10 5 CFU/ml of urine, and ≥ 5 WBC per high power light microscopy field.
Wound infection
Purulent discharge from wounds, a culture yielding ≥ 3+ or ≥ 10 5 CFU/ml and signs of local inflammation. Isolation of skin flora is considered to be contamination.
Statistical analysis
The t-test test was used to determine the significance of differences for age, length of stay in ICU, and days of ventilation in Groups A and B. The Chisquare test was used to evaluate the MRSA carrier state between the two groups. Non-parametric tests (Mann-Whitney and Wilcoxon test) were performed in order to evaluate the SAPS II values and to compare the incidence of primary endogenous, secondary endogenous and exogenous infections in Groups A and B and within both groups. Statistical significance was defined as a P value of less than 0.05. The first episode was used for statistical analysis in patients who had more than one MRSA infection. The statistical analysis was calculated by the SPSS statistical analyzer release 8.0 (SPPS Inc.; Chicago, 1997).
RESULTS
General characteristics
From March 1, 1998 until February 29, 2000 1311 patients were admitted to the intensive care unit. Overall 271 patients were eligible for inclusion in the study. Six patients were excluded due to violation of the study protocol leaving 265 for analysis: 123 in Group A and 142 in Group B. Carriage of MRSA A total of 126 patients (47.5%) were found to carry MRSA during the two-year study. The microorganism was imported into the ICU in 30 (24%) patients, as surveillance cultures on admission were positive for MRSA. Ninety-six (76%) patients acquired the MRSA during the ICU stay (nosocomial). Nosocomial MRSA carriage developed at a median of 9 days (IQR, 6-15). Group A showed a MRSA carriage rate of 54% (67/123). Thirteen patients imported the bacterium, and 54 acquired MRSA during ICU stay. Fifty-nine of 142 subjects in Group B (42%) carried MRSA, of whom 17 imported the microorganism and 42 acquired it in the ICU. The oropharyngeal swab only was positive for MRSA in 60 patients, whilst MRSA was isolated from the rectal swab alone in 9 patients. The remaining 57 subjects carried MRSA in both oropharynx and rectum.
There was no difference in median SAPS II scores 43.5 (IQR, 37-52) in MRSA carriers, and 45 (IQR, 35-55) in patients without MRSA carriage.
Surgical tracheostomy was performed in 61 patients at median of 14 days (IQR 2-21) and 10 days (IQR 1-18) in Group A and Group B, respectively. Forty-two (68.9%) of 61 tracheostomized patients developed MRSA carriage in the oropharynx and/or rectum compared to 84/204 (41%) MRSA carriers without tracheostomy (P<0.001).
Mortality was identical between MRSA carriers (41/126=32.5%) and patients who were free from MRSA (45/139=32.4%).
Sixty-seven and 59 MRSA carriers were identified in Groups A and B, respectively. Twenty-one patients did not receive the vancomycin intervention (12 in Group A and 9 in Group B) because the results of the surveillance swabs were only known after extubation or discharge from the ICU. In total 105 (40% of the study population) received the study intervention: Group A included 55 subjects and Group B, 50 patients (Table 4) .
Oral MRSA carriage was abolished in 25 (45.5%) out of 55 patients in Group A. The throat swabs became negative for MRSA in 28 of the 50 oropharyngeal carriers (61%) receiving the 4% vancomycin. The oropharyngeal carriage rate of MRSA was significantly less after one week of 4% vancomycin gel administration compared with 2% vancomycin gel (P<0.05). Thirty-three and 28 rectal carriers were identified in Group A and B, respectively. Rectal swabs were negative following administration of 1.0 g of enteral vancomycin solution in 22 (66.7%) and 20 (71.4%) patients, in Group A and Group B respectively.
Absolute carriage of MRSA
The absolute carriage was invariably high at 3.6 and 3.2 as 80% of the long stay patients had overgrowth of >3+, at the start of the vancomycin protocol both low and high doses (Figure 1 ). The contribution of the MRSA patients who required prolonged mechanical ventilation and who received the vancomycin protocol, to the absolute carriage was significantly reduced after one week of vancomycin, from 3.6 to 2.6 (P<0.01) in Group A and from 3.2 down to 1.5 (P<0.001) in Group B. The efficacy of the 4% vancomycin gel was significantly higher compared with the 2% vancomycin gel after one week (s2) (P<0.01).
Thirty-nine patients in Group A (71%) who received the 2% vancomycin protocol, and 29 patients (52%) on 4% vancomycin in Group B had surveillance cultures of throat and rectum still yielding MRSA, albeit in low concentrations. The absolute carriage for oropharyngeal MRSA was 1.4 after three weeks (sample 6) of the lower dose of vancomycin, whilst the absolute carriage was 0.8 in the group 366 M. VIVIANI, H. K. F. VAN receiving the higher dose of vancomycin but the difference was not significant (P=0.63). The absolute carriage for rectal MRSA was always low throughout the study period.
Infections due to MRSA
During the whole study, 43 of the 265 long-term ventilated patients (16.2%) developed 55 infections due to MRSA. The median interval between the admission and the onset of infection was 12 days (IQR, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . There were 18 primary endogenous infections with a median onset of two days. The median onset of the 31 secondary endogenous episodes was 13 days (IQR, [18] [19] [20] [21] [22] [23] [24] . The onset of the 6 exogenous infections was 18.5 days.
Twenty-seven MRSA infections in Group A were diagnosed in 21 patients receiving enteral vancomycin (Table 4) . Twenty-four episodes caused by MRSA in Group B were documented in 18 patients. Primary endogenous and exogenous infections did not differ between the two groups (Table 4) . A significant reduction (P<0.05) of the secondary endogenous infection episodes due to MRSA was found in the patients receiving 4% gel rather than 2% gel (15 episodes were observed in Group A and 7 in Group B).
VISA and VRE
A total of 3588 microbiological samples were processed, 2718 surveillance and 870 diagnostic samples. Neither S. aureus with intermediate susceptibility to vancomycin (VISA) nor enterococci resistant to vancomycin (VRE) were isolated.
DISCUSSION
Three observations emerge from this two-year sequential dose-response study:
( FIGURE 1: Impact of a low (2%) and high (4%) dose of oral vancomycin gel on the absolute carriage. The absolute carriage was high in the first surveillance samples positive for MRSA (s0) in both groups as 80% of the patients carried MRSA in overgrowth in the oropharynx. The absolute carriage at oral level was significantly lower at the 2nd (s1) and at the 3rd sample (s2) in the Group B compared to Group A. (*P<0.01). The absolute carriage at rectal level was low throughout the 2 year study in both groups.
Oropharynx (vancomycin 2%) (Group 4)
Oropharynx (vancomycin 4%) (Group B)
Gut (1g of vancomycin) (Groups A and B)
Samples long stay patients on the unit was invariably high during both study periods of low and high doses of oral vancomycin (3.6 and 3.2) as 80% of the patients receiving the study manoeuvre carried MRSA in overgrowth. However, the 4% vancomycin manoeuvre significantly reduced the absolute carriage compared to the 2% vancomycin intervention (2.6 versus 1.5, P<0.01). (ii) There were significantly more patients with secondary endogenous MRSA infections in Group A receiving the lower doses of vancomycin compared to the group B on the higher 4% vancomycin dose (15 versus 7, P<0.05). (iii) VRE and VISA were not isolated from surveillance or diagnostic samples. Observations on the characteristics of outbreaks of infection show that once one third of the ICU population carry MRSA, spread via the hands of carers is impossible to prevent and outbreaks of carriage and/or infection difficult to avoid. The proportion of patients who carry resistant microorganisms has been recognized as an important risk factor for endemicity or ongoing uncontrolled outbreaks 26 . Only a few studies evaluated the level of carriage as a variable in the pathogenesis of outbreaks besides the carriage rates. One English 27 and one Italian 28 study report on the control of two outbreaks due to Candida parapsilosis and due to MRSA following the administration of enteral nystatin and vancomycin. They demonstrated that the outbreaks were under control once the level of carriage of the outbreak strain was low, even when the proportion of carriers was not always significantly reduced. Apparently, transmission was significantly less once the carriage indices for C. parapsilosis and MRSA were <1, i.e., the surveillance swabs became positive only after enrichment broth. These data are confirmed by a more recent Spanish study showing that patients had not to be completely negative for MRSA in their surveillance samples to be kept free from MRSA in blood and lower airways 29 . Control of MRSA overgrowth was sufficient to prevent the internal organs from being colonized and infected with MRSA. Overgrowth of MRSA was shown to be a risk factor for invasive infection and transmission of MRSA. This is the first study that combines carriage rates and levels of the MRSA strain to evaluate: (i) The absolute carriage which reflects the longterm ventilated patients as the animate source of MRSA on the unit; (ii) The impact of the intervention of oral vancomycin in low and high doses on the absolute carriage of the long stay patients on the unit.
The strategy based on the detection and treatment of nasal carriers of MRSA implies that the reservoir of MRSA is the anterior nares 19, 30, 31 . However, there is increasing evidence that the cultures of throat and perineum/rectum have a higher sensitivity in identifying carriers of MRSA compared to nasal cultures 29, 32, 33 . Additionally, recent studies showed that five days of enteral vancomycin were more effective in eradicating MRSA carriage compared to five days of mupirocin, as mupirocin failed to clear throat and gut carriage 28, 29, 34 . For these reasons, oropharyngeal and rectal samples were obtained and the patients received enteral vancomycin rather than nasal mupirocin for MRSA decontamination during our study. Practically all ICU patients who were MRSA carriers were positive in the oropharynx (93%), whilst gut carriage was present in about half of the carriers (52%). The semi-quantitative culturing of the surveillance samples of throat showed that MRSA carriers who required long-term ventilation carried MRSA in overgrowth concentrations before receiving the study intervention.
Combining rates and levels allows the estimation of the absolute carriage in an ICU. This reflects the long-term ventilated patients as the animate source of MRSA on the unit. In this study the absolute carriage was invariably higher than 3, in 85% of the patients with MRSA. We believe that the level of carriage is as important as the number of patients who are admitted as carriers to or became carriers on the unit. Although the five infection control manoeuvres including isolation, hand hygiene, protective clothing, care of equipment and environment aim to control dissemination of MRSA in the unit, the risk of acquiring MRSA due to transmission via hands of carers on a unit with an absolute carriage of 3 must be higher than on a unit where the patients carry MRSA in low concentrations. These circumstances were achieved following the administration of vancomycin in throat and gut in order to eradicate overgrowth of MRSA. During the first year of the trial the lower dose of 2% vancomycin gel lowered the absolute carriage from 3.6 to 2.6, but the impact of the 4% vancomycin gel during the second year was even higher from 3.2 to 1.5 (P<0.001). As vancomycin inactivation by salivary components is substantial 35 , it is plausible that the bactericidal concentrations achieved in saliva were higher following the daily application of 4 ml of 4% vancomycin gel compared to the 2% vancomycin gel. Our data support the findings in three other studies using 4% vancomycin in the oropharynx 16, 29, 36 . The MRSA concentrations were significantly lower in the samples following vancomycin protocol, de-spite more than half the patients still carrying MRSA. Apparently, completely eradicating MRSA using enteral vancomycin is difficult, but not necessary as reducing the level of carriage from overgrowth concentrations (3+ in the second quadrant) down to very low levels (1+ in the enrichment broth) is effective in controlling both transmission and secondary endogenous infections. A similar experience has been reported for yeast eradication by polyenes 27 . In contrast to MRSA and yeasts, aerobic Gram-negative bacilli eradication using polymyxin E and tobramycin is more successful in abolishing both rates and levels 37, 38 . Significantly less patients developed secondary endogenous infections due to MRSA during the second year when the higher vancomycin dose was used compared to the lower dose in the first year (7 patients versus 15 patients, P<0.05). These findings may be explained by the significantly lower risk of transmission once the absolute carriage of the patients on the unit is less than 1, i.e., if a patient carries MRSA on the unit, the level is always very low. Superinfection or secondary endogenous infection due to MRSA, acquired on the unit, invariably develop "late", at least after one week (13 days in this study), and therefore are preventable by the application of oral and enteral vancomycin. Primary endogenous infections due to MRSA present in the admission flora tend to develop "early" within one week (two days in this study) and require the immediate administration of parenteral vancomycin. Exogenous infections are caused by a potential pathogen not carried at all in throat and gut. There were two exogenous infections in each year of this study. Inability to control exogenous infections is an inherent limitation of enteral antibiotics. High standards of hygiene are essential to prevent such infections. It is important to realise that the design of this study was not the prevention of the MRSA carrier state, but the treatment of carriage as soon as the carrier state was detected. One recent study used enteral vancomycin in high risk patients to prevent the MRSA carrier state and demonstrated that prevention is more effective than treating carriers 29 . S. aureus sensitive to methicillin does not become MRSA, therefore import of MRSA followed by dissemination is required for endemicity. Hence, detection and control of MRSA import is an integral component of the control of MRSA endemicity. Transmission and subsequent dissemination are unavoidable if import is undetected. This study combined qualitative (rates) and quantitative (levels) data of MRSA carriage, both imported and acquired, enabling the estimation of the absolute carriage. The significantly reduced absolute carriage in the doseresponse study illustrate that control of MRSA import is indispensable if we want to curb ongoing MRSA endemicity 31, 39 . The comparison of different consecutive periods provides a lower level of evidence than a controlled clinical trial in order to establish a causal relationship between the intervention assessed and the results. However, the sequential design is considered to be a valid method to report the association between the absolute carriage and infection and the implemented manoeuvres for the following reasons 21, 40 . Firstly, the comparison between the demographics of the patients in the two periods supports the similarity of the patients in the study. Secondly, the percentage of patients who imported MRSA was similar in the two periods suggesting that the number of imported MRSA cases did not have a significant impact on the results of the study. Thirdly, in a randomized design the patients who receive the lower dose of vancomycin gel may benefit from the manoeuvre of the higher doses of vancomycin in that the patients receiving 4% of vancomycin are likely to be more successfully decontaminated than the patients with the lower doses. Transmission of MRSA is likely to be less from the patients receiving the higher concentration towards the group with the lower concentration.
The main concern about the use of enteral vancomycin is the emergence of VISA and VRE 41, 42 . Vancomycin sensitive enterococci are unlikely to mutate into vancomycin resistant under selection pressure from vancomycin, this event requires extensive genetic changes which occur very rarely. However, widespread use of ciprofloxacin in both community 43 and hospital 44 during the nineties has been responsible for a heavy selection pressure towards Gram-positive cocci leading to enterococcal 45 and staphylococcal 46 overgrowth in the gut. Additionally, it is crucial to realize that 2 g of vancomycin results in faecal vancomycin levels between 6 and 11 µg/g of faeces following the intravenous route but to intestinal concentrations varying between 3,000 and 24,000 µg/g of faeces after oral administration 47, 48 . Most patients who require ventilation for a minimum of five days receive the popular combination of ciprofloxacin and vancomycin intravenously as a "broad" cover for Gram-negative and Gram-positive organisms 49, 50 . This common scenario of staphylococcal and/or enterococcal overgrowth in the presence of fluctuating non-lethal vancomycin levels in the gut following biliary excretion, may have contributed to the emergence of VRE and VISA 51, 52 . Extensive efforts have been made in this study to evaluate about 3,600 samples for the possibility of colonization/infection with VRE and VISA and of overgrowth of VRE and VISA. Rigid screening for the two target microorganisms failed to detect either VRE or VISA over two years. It is important to realise that the oropharyngeal and intestinal vancomycin protocols were studied in an intensive care and hospital setting with no experience of VRE. VRE, in general, is imported into the ICU and therefore, it is not feasible to speculate on the possibility of increasing rates of VRE. However, our data is in line with two recent studies using enteral vancomycin in both intensive care and hospital settings without VRE emerging 53, 54 . SDD, including enteral vancomycin, has been evaluated in seven studies in mechanically ventilated patients 36 . None of the studies report an increased infection rate due to VRE or VISA. Two European studies, evaluated SDD including vancomycin on intensive care units without VRE history, and in one study VRE was imported into the unit but no change in policy was required as rapid and extensive spread did not occur. The American study was conducted in a unit with a low incidence of VRE infection and reported that SDD did not increase the incidence of VRE carriage and infection 55 .
CONCLUSIONS
The selected use of oral vancomycin in less than 10% of the whole population referred to the ICU and in less than 40% of the long-term ventilated patients contributed to the control of MRSA and subsequent endemicity in the unit. The use of 4% vancomycin gel resulted in a significant reduction of secondary endogenous MRSA infections following the significantly reduced absolute carriage. We were unable to confirm the concerns that the enteral vancomycin leads to the emergence of vancomycin resistance amongst MRSA and enterococci over a period of two years. 
